Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial

Y. Vanrenterghem, J.P. van Hooff, J.P. Squifflet, K. Salmela, P. Rigotti, R.M. Jindal, J. Pascual, H. Ekberg, L.S. Sicilia, J.N. Boletis, J.M. Grinyo, M.A. Rodriguez, Group Eur. Tacrolimus/MMF Renal TrPl

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Modern immunosuppressive regimens reduce the acute rejection rate by combining a cornerstone immunosuppressant like tacrolimus or cyclosporine with adjunctive agents like corticosteroids, mycophenolate mofetil (MMF) or azathioprine, often associated with untoward side effects. A 6-month randomized study was conducted in 47 European centers. Triple therapy with tacrolimus (trough levels 5-15 ng/mL), corticosteroids (dosage 10 mg/day) and MMF (1 g/day) was administered for 3 months. From day 92, patients either continued with triple therapy (control, n = 277), or stopped steroids (n = 279), or stopped MMF (n = 277). Surrogate markers for long-term benefits were changes in lipid profiles and occurrence of hematological, gastrointestinal and infectious complications. The 6-month acute rejection incidence (biopsy-proven) was similar in all groups (17.0% vs. 15.1% vs. 14.8%, p = 0.744), although the incidence after month 3 was higher in the steroid stop group than in the two other groups. Mean reductions in total cholesterol (18.9 mg/dL [0.49 mmol/L]) and LDL-cholesterol (8.1 mg/dL [0.21 mmol/L]) between months 4 and 6 were greater in the steroid stop group (p < 0.001). Leukopenia (p = 0.0082), serious CMV infection (p = 0.024), anemia (p = NS) and diarrhea (p = NS) were less frequent in the MMF stop group. In a study population of immunologically low-risk patients' withdrawal of corticosteroids or MMF from a tacrolimus-based therapy at 3 months was feasible. A longer follow-up will be needed to confirm the expected advantages for the long-term outcome and to assess the long-term safety of this minimization of immunosuppressive therapy
Original languageEnglish
Pages (from-to)87-95
JournalAmerican Journal of Transplantation
Volume5
Issue number1
DOIs
Publication statusPublished - 1 Jan 2005

Cite this

Vanrenterghem, Y., van Hooff, J. P., Squifflet, J. P., Salmela, K., Rigotti, P., Jindal, R. M., Pascual, J., Ekberg, H., Sicilia, L. S., Boletis, J. N., Grinyo, J. M., Rodriguez, M. A., & Eur. Tacrolimus/MMF Renal TrPl, G. (2005). Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. American Journal of Transplantation, 5(1), 87-95. https://doi.org/10.1111/j.1600-6143.2004.00638.x